Gilead Raises 2020 Profit Outlook on Remdesivir Demand

Gilead Sciences Inc. expects sales of its Covid-19 drug remdesivir to help lift its full-year revenue by as much as $2.8 billion in 2020, offsetting the negative impact of the pandemic on some of its other medicines.

Gilead Raises 2020 Profit Outlook on Remdesivir Demand
Gilead Sciences Inc. expects sales of its Covid-19 drug remdesivir to help lift its full-year revenue by as much as $2.8 billion in 2020, offsetting the negative impact of the pandemic on some of its other medicines.